China's stock market is arrogant, and overseas Chinese stocks have returned to A-shares! In the United States listed the medical equipment business Mindray Medical (Mindray Medical International) 4 announced soon under the city, back to the Chinese stock market listing. Mindray jumped 11% on the 4th, creating the biggest gain in nearly three years.
According to the offer of the Harvest XQ Global Winner System, Mindray rose 10.92% on the 4th to close at 30.47 US dollars, the highest since August 2012. The volume was 6.52 million shares, which is more than 9 times the average daily trading volume in the past three months.
Bloomberg reported that Mindray’s three top executives controlled 28% of the company’s shares, and the three announced that they would acquire foreign shares at $30 per share. This price is 9.2% higher than the 3rd closing price of 27.47 US dollars, which is estimated to cost about 2.6 billion US dollars. Peter Halesworth, founder of Heng Ren Investments, said that although the pharmaceutical biotech stocks are highly valued in China, the US dollar valuation is better, and Mindray should be selected for the stock price.
Recently, China-listed Chinese stocks have set off a wave of returnees. In April, China Cord Blood Corp. and Wu Xi Pharma Tech all chose to return to China. Mindray was listed in the US in September 2006. The current price is 18 times the estimated earnings, which is 58 times lower than that of A-share companies.
In order to improve the outflow of funds, China actively encourages Chinese stocks to return to China. The Wall Street Journal reported on May 19 that sources said that the Shanghai Stock Exchange will set up the Strategic Emerging Industries Board, which is the innovation-oriented industry favored by Beijing, including computer science, information technology, renewable energy, Operators such as the biological sciences will be listed here. It is said that this proposal has been approved by the China Securities Regulatory Commission and may be on the road at the end of this year, directly on the Shenzhen GEM.
Lu Media Zhongjin Online reported on May 20 that the statistics of "21st Century Business Herald" show that more than 1,200 Chinese companies have been listed overseas, with a market capitalization of 2.5 trillion US dollars. In recent years, many Chinese SME stocks have been Overseas stock prices are sluggish, so since 2010, China Stocks has been intensively delisted. 85% of these companies belong to the service category of strategic emerging board. The financial market said that if the SSE's strategic emerging board is launched, one of the important functions is to undertake overseas Chinese stocks to go back to China.
However, the venture capital industry is booming in China, and some experts believe that the most sweet stage of China's venture capital industry has ended. Bloomberg reported on May 21 that the 52-year-old venture capitalist Stephen Bell spent seven years looking for opportunities in China. Since 2009, he has invested in about 50 startups. However, as the market value of Chinese start-ups has risen sharply, he believes that the time to be cheap is over.
Health Care Products,Urine Collection Bag,Blood Glucose Tester,Stoma Care Products
Puyang Degren Medical Equipment Co., Ltd. , https://www.degrenyuwei.com